Securities code: Zhejiang Gongdong Medical Technology Co.Ltd(605369) securities abbreviation: Zhejiang Gongdong Medical Technology Co.Ltd(605369) Announcement No.: 2022014
Zhejiang Gongdong Medical Technology Co.Ltd(605369)
Special report on the annual storage and use of raised funds
(2021)
The board of directors and all directors of the company guarantee that there are no false records, misleading statements or major omissions in the contents of this announcement, and bear individual and joint liabilities for the authenticity, accuracy and completeness of its contents.
According to the self regulatory guidelines for listed companies of Shanghai Stock Exchange No. 1 – standardized operation (SZF [2022] No. 2) and relevant format guidelines issued by Shanghai Stock Exchange, the special description of the deposit and use of the company’s raised funds in 2021 is as follows.
1、 Basic information of raised funds
(I) actual amount of raised funds and receipt of funds
Approved by the reply on approving Zhejiang Gongdong Medical Technology Co.Ltd(605369) initial public offering of shares (zjxk [2020] No. 1905) of China Securities Regulatory Commission and approved by Shanghai Stock Exchange, Zhejiang Gongdong Medical Technology Co.Ltd(605369) initial public offering of 20 million RMB common shares (A shares), with an issue price of 31.65 yuan per share and a total raised capital of 63300000000 yuan, After deducting the issuance expenses of 5485990566 yuan, the net amount of raised funds is 57814009434 yuan. The funds raised by this public offering of shares have arrived on September 10, 2020. Tianjian Certified Public Accountants (special general partnership) issued the capital verification report (tjy [2020] No. 359) on September 10, 2020 to verify the arrival of the raised funds.
(II) use and balance of raised funds
As of December 31, 2021, the use and balance of the company’s raised funds are as follows:
Unit: RMB 10000
Item No. amount
Net amount of raised funds a 5781401
Project investment B12016808 as of the beginning of the period, the balance of funds raised at the beginning of the period for cash management B22500000
Net interest income after deducting handling charges B3 99.24
Project input C12560538
Raised funds for cash management note C21300000
The amount incurred in the current period redeems the raised capital C32700000 for cash management
The raised funds are used for cash management and the income is c478869
Net amount of interest income after deducting handling charges c511332
Project investment D1 = B1 + C14577346
By the end of the period, the accumulated balance of the raised funds for cash management D2 = B2 + C2-C31100000
Income from the raised funds used for cash management D3 = C4 788.69
Net amount of interest income after deducting handling charges D4 = B3 + C5 212.56
Balance of fund raised e = a-d1 – 204180 D2 + D3 + D4
Actual balance of raised funds f 204180
Difference g = E-F 0.00
Note: after the 14th meeting of the first board of directors and the 11th meeting of the first board of supervisors on September 28, 2020, October 20, 2020
On June 15, the first extraordinary general meeting of the company in 2020 approved that the company should use the idle land with a total amount of no more than RMB 250 million
Purchase and raise funds for cash management.
After deliberation and approval at the 11th meeting of the second board of directors and the 8th meeting of the second board of supervisors on October 21, 2021, it is agreed that the company will use idle raised funds with a total amount of no more than RMB 150 million for cash management.
As of December 31, 2021, the balance of idle raised funds used by the company for cash management was 110 million yuan, all of which were deposited in the designated account of Industrial And Commercial Bank Of China Limited(601398) Taizhou Huangyan sub branch (Account No.: 12070311420 Hunan Gold Corporation Limited(002155) 9).
2、 Management of raised funds
(I) management of raised funds
In order to standardize the management and use of raised funds, improve the efficiency and efficiency of fund use, and protect the rights and interests of investors, In accordance with the company law of the people’s Republic of China, the securities law of the people’s Republic of China, the Listing Rules of Shanghai Stock Exchange (revised in January 2022) (SZF [2022] No. 1) and the self regulatory guidelines for listed companies on Shanghai Stock Exchange No. 1 – standardized operation (SZF [2022] No. 2) and other relevant laws, regulations and normative documents, and in combination with the actual situation of the company, The administrative measures for Zhejiang Gongdong Medical Technology Co.Ltd(605369) raised funds (hereinafter referred to as the administrative measures) has been formulated.
According to the management measures, the company implements special account storage for the raised funds, establishes a special account for the raised funds in the bank, and together with the sponsor Zhongtai Securities Co.Ltd(600918) signed the tripartite supervision agreement on the storage of the special account for raised funds with Bank Of China Limited(601988) Huangyan sub branch on September 10, 2020, clarifying the rights and obligations of all parties. There is no significant difference between the tripartite regulatory agreement and the model tripartite regulatory agreement of Shanghai Stock Exchange, and the company has strictly complied with the raised funds. As of December 31, 2021, the above regulatory agreements have been performed normally.
(II) storage of raised funds in special account
As of December 31, 2021, the company has a special account for raised funds, and the deposits of raised funds are as follows:
Unit: RMB
Remarks on the balance of raised funds in the account number of the deposit bank
Bank Of China Limited(601988) Huangyan Beicheng sub branch 4026784298132041800135
Total – 2041800135
3、 Actual use of raised funds in 2021
(I) use of funds for investment projects with raised funds
In 2021, the total amount of funds used for projects invested with raised funds was RMB 256053800, of which the amount directly invested in projects invested with raised funds was RMB 256053800.
As of December 31, 2021, the total amount of funds used in raised investment projects is 4577346 million yuan, of which 1288921 million yuan is used to replace the self raised funds invested in raised investment projects in advance and 3288426 million yuan is directly invested in raised investment projects (including 330733 million yuan of “supplementary working capital” projects). See attached table 1: comparison table of use of raised funds for details.
(II) early investment and replacement of raised investment projects
In 2021, the company did not have any early investment and replacement of raised investment projects.
The advance investment and self raised funds of raised investment projects have been replaced in 2020. For details, please refer to the website of Shanghai Stock Exchange (www.sse. Com. CN.) Announcement on using raised funds to replace self raised funds of pre invested raised projects (Announcement No.: 2020007).
(III) temporary replenishment of working capital with idle raised funds
As of December 31, 2021, the company has not used idle raised funds to temporarily supplement working capital.
(IV) cash management and investment of idle raised funds in related products
1. The company held the 14th meeting of the first board of directors and the 11th meeting of the first board of supervisors on September 28, 2020, and the first extraordinary general meeting of shareholders in 2020 on October 15, 2020. The proposal on using some idle raised funds for cash management was reviewed and approved, and the company was agreed to use idle raised funds with a total amount of no more than RMB 250 million for cash management; At the same time, authorize the chairman or general manager to exercise the investment decision-making power and sign relevant contract documents, which shall be implemented by relevant departments of the company; Effective within 12 months (including 12 months) from the date of deliberation and approval of the first extraordinary general meeting of shareholders in 2020. The independent directors of the company expressed their independent opinions on the matter, and Zhongtai Securities Co.Ltd(600918) issued the verification opinions on Zhejiang Gongdong Medical Technology Co.Ltd(605369) using some idle raised funds for cash management.
For details, please refer to the website of Shanghai Stock Exchange (www.sse. Com. CN.) Announcement on using some idle raised funds for cash management (Announcement No.: 2020008).
2. Approved by the 11th meeting of the second board of directors and the 8th meeting of the second board of supervisors on October 21, 2021, it is agreed that the company will use the idle raised funds with a total amount of no more than RMB 150 million for cash management; Within 12 months (including 12 months), the fund can be used on a rolling basis; Authorize the chairman or general manager to exercise the investment decision-making power and sign relevant contract documents, which shall be implemented by relevant departments of the company.
The independent directors of the company expressed their independent opinions on the matter, and Zhongtai Securities Co.Ltd(600918) issued the verification opinions on Zhejiang Gongdong Medical Technology Co.Ltd(605369) using some idle raised funds for cash management.
For details, please refer to the website of Shanghai Stock Exchange (www.sse. Com. CN.) Announcement on using some idle raised funds for cash management (Announcement No.: 2021041).
3. As of December 31, 2021, the balance of idle raised funds used by the company for cash management was 110 million yuan, all of which were deposited in the designated account of Industrial And Commercial Bank Of China Limited(601398) Taizhou Huangyan sub branch (Account No.: 12070311420 Hunan Gold Corporation Limited(002155) 9).
(V) permanent replenishment of working capital or repayment of bank loans with over raised funds
Not applicable.
(VI) use of over raised funds for projects under construction and new projects (including acquisition of assets, etc.)
Not applicable.
(VII) use of surplus raised funds
As of December 31, 2021, the “supplementary working capital” project in the raised investment project has been implemented, and there is no surplus fund; Other raised investment projects have not been completed, and there is no surplus raised funds.
(VIII) description of the situation that the benefits of the investment projects with raised funds cannot be calculated separately
1. The construction of “R & D center construction project” is conducive to improving the overall R & D strength of the company and maintaining technology leadership. At the same time, the construction of the project will effectively improve production efficiency, product quality and customization ability, and the project itself will not directly produce benefits;
2. The “supplementary working capital” project is mainly to meet the needs of the continuous expansion of the company’s business scale for working capital. The company improves its financial strength, further reduces financial risks and improves its financial structure. It is impossible to calculate the benefits separately.
(IX) other information about the use of raised funds
As of December 31, 2021, the company has no other use of raised funds.
4、 Change the use of funds for investment projects with raised funds
After deliberation at the 11th meeting of the second board of directors and the 8th meeting of the second board of supervisors on October 21, 2021, through the overall adjustment of the production line planning and layout of the company’s plants and production workshops, the production efficiency is improved, the production management cost and material transfer cost are reduced, and the use efficiency of raised funds is improved
